Chugai Of Japan Reveals Deaths In Local Study Of Arthritis Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical, now a subsidiary of Roche, has disclosed its Actemra (tocilizumab) drug for treating rheumatoid arthritis may be connected with the deaths of 15 patients. The company did not deny a connection between its drug and the deaths, but said it would supply more information to physicians about side effects. The study in which the deaths occurred involved nearly 5,000 people in Japan where the study was required after it was approved. The drug also has EU approval, but not in the United States. (Click here for more - a subscription may be required